Moderna’s new Covid vaccine generated a strong immune response against BA.2.86, a highly mutated omicron variant that health officials are watching closely, according to clinical trial data the biotech company released Wednesday.
Moderna’s new Covid vaccine generated a strong immune response against BA.2.86, a highly mutated omicron variant that health officials are watching closely, according to clinical trial data the biotech company released Wednesday.
Johnson & Johnson on Wednesday forecast 12.5% growth in its annual adjusted profit after completing the separation of consumer health company Kenvue .
Drugmakers Dechra and Hikma along with retailer Marks & Spencer and technical products provider Diploma are set to join the UK’s blue-chip FTSE 100 index in September, indicative changes announced by FTSE Russell show.
Novavax Inc said on Tuesday its updated protein-based COVID-19 vaccine generated an immune response against the “Eris” subvariant in preclinical studies.
Moderna’s new Covid vaccine generated a robust immune response against the now-dominant Eris variant and another rapidly spreading strain of the virus in an early clinical trial, the biotech company said Thursday.
The latest version, which some are calling Eris, is now a “variant of interest” at the World Health Organization, having been reported in at least 51 countries since early August, including China, the U.S., Korea, Japan, and Canada.
Novo Nordisk, which makes blockbuster drug Wegovy, raised its outlook for 2023 Thursday but said it is extending supply restrictions for some doses of the weight-loss drug.
Kenvue–0.13% will join the S&P 500SPX –0.70% following the completion of Johnson and Johnson JNJ –0.06% ’s exchange offer for Kenvue stock, according to S&P Dow Jones Indices.
Shares of Danish drugmaker Novo Nordisk soared on Tuesday, after late-stage trial data showed that its obesity drug Wegovy reduced the risk of major cardiovascular events such as heart attacks or strokes by 20%, compared with a placebo.
Eli Lilly stock was flying on Tuesday after the drugmaker recorded quarterly profit and revenue well ahead of Wall Street’s expectations. Sales of obesity drugs are delivering the goods.
Shares of BioNTech, the German company that developed a Covid-19 vaccine with Pfizer , were falling in early trading Monday after second-quarter revenue missed expectations.the U.S. dollar strengthened versus major rivals.
Moderna shares were rising early Thursday after the company reported lighter losses and better revenue than expected for the June quarter and raised guidance for sales of its Covid-19 vaccine.
Merck on Tuesday reported second-quarter revenue that topped expectations on strong sales of its blockbuster cancer drug Keytruda and HPV vaccine Gardasil.
Biogen said Friday it will acquire Reata Pharmaceuticals in a deal valued at $7.3 billion.
July 27 (Reuters) – Eli Lilly (LLY.N) said on Thursday its experimental obesity drug met the main goals in two late-stage studies, with the drug helping patients reduce 26.6% weight on average in one of the studies following intensive lifestyle changes.
LONDON July 26 – GSK raised its full-year profit and sales guidance on Wednesday after its second-quarter earnings beat expectations, helped by strong sales of its shingles vaccine Shingrix and HIV medicines.
.
Johnson & Johnson on Thursday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations due to strong sales growth from the company’s medtech business.
FRANKFURT, July 18 (Reuters) – Novartis (NOVN.S) on Tuesday raised its full-year earnings forecast for the second time on strong drug sales and mapped out the planned separation and stock market debut of its generic medicines division Sandoz for early October.
Gilead GILD +0.57% Sciences recently spent about $30 million to increase its stakes in two biotech stocks.
Shares of Covid-19 manufacturer Novavax were surging after the company said it will receive $350 million from Canada to settle forfeited vaccine doses that were supposed to be delivered.